Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin

The Lancet

Volumn 339, Issue 8807, 1992, Pages 1476-

  Green, David ^a,b   Hull, RussellD ^a,b   Brant, Rollin ^a,b   Pineo, GrahamF ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; THROMBOSIS;

HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN; NEOPLASMS;

EID: 0026762705     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(92)92064-M     Document Type: Letter

References (10)

1. Review: low molecular weight heparin
2. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
3. Subcutaneous low molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
4. Suppression by heparin of smooth muscle cell proliferation in injured arteries
5. Endothelial cell reactions with heparin
6. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid
7. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone
8. Suramin: an anticancer drug with a unique mechanism of action
9. Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex
10. Anionic dyes, heparin and heparinoids: the rediscovery of polyanionic tumor inhibitors